Views: 1,474 | Downloads:
17
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
The Efficacy and Safety of Lyophilized Cryoprecipitate in Hemophilia A
Chuansumrit A 
,
sarangkura P ,
Chantanakajomfung A ,
Kuhathong K ,
Pintadit P ,
Jitpraphai C ,
Hathirat P ,
Nuchprayoon C
,
sarangkura P ,
Chantanakajomfung A ,
Kuhathong K ,
Pintadit P ,
Jitpraphai C ,
Hathirat P ,
Nuchprayoon C This prospective study of assessing the efficacy and safety of lyophilized cryoprecipitate
(LC), which was heat-treated at 60°C for 25 hours, was conducted in 23 patients with hemophilia
A (severe 13, moderate 9, mild 1) at the International Hemophilia Training Center, Bangkok from
1997 to 1998. A total of 223 infusions of LC were given. The status of the patients could be
classified into 4 groups : group I, non-bleeding (n = 13); group II, severe bleeding requiring hospitalization
(n = 9); group III, appendectomy (n = 1) and group IV, early bleeding controlled by
modified home treatment (n = 200). Pharmacokinetic studies were conducted in groups I and II.
The mean in vivo half-life of factor VIII clotting activity (F VIII:C) was 12.6 hours and the mean
in vivo incremental recovery at baseline was 2.1 per cent/unit/kg. The mean clearance was 3.22
mVkglh. There was no statistically significant difference in these parameters between groups I
and II (p > 0.05). The hemostasis was successfully achieved and 1 to 2 small urticarial wheals
were observed in only 2 infusions. In addition, 9 out of 23 patients received LC exclusively for
1 year. None of them developed inhibitor to F VIII:C nor did any contract additional transfusion-
transmitted infection except one who developed anti-hepatitis C virus seroconversion
after receiving 16 bottles of LC in 4 months. Therefore, the more efficient virus-inactivation in the
preparation of LC should be established.
Key word : Lyophilized Cryoprecipitate, Hemophilia, Efficacy, Safety
(LC), which was heat-treated at 60°C for 25 hours, was conducted in 23 patients with hemophilia
A (severe 13, moderate 9, mild 1) at the International Hemophilia Training Center, Bangkok from
1997 to 1998. A total of 223 infusions of LC were given. The status of the patients could be
classified into 4 groups : group I, non-bleeding (n = 13); group II, severe bleeding requiring hospitalization
(n = 9); group III, appendectomy (n = 1) and group IV, early bleeding controlled by
modified home treatment (n = 200). Pharmacokinetic studies were conducted in groups I and II.
The mean in vivo half-life of factor VIII clotting activity (F VIII:C) was 12.6 hours and the mean
in vivo incremental recovery at baseline was 2.1 per cent/unit/kg. The mean clearance was 3.22
mVkglh. There was no statistically significant difference in these parameters between groups I
and II (p > 0.05). The hemostasis was successfully achieved and 1 to 2 small urticarial wheals
were observed in only 2 infusions. In addition, 9 out of 23 patients received LC exclusively for
1 year. None of them developed inhibitor to F VIII:C nor did any contract additional transfusion-
transmitted infection except one who developed anti-hepatitis C virus seroconversion
after receiving 16 bottles of LC in 4 months. Therefore, the more efficient virus-inactivation in the
preparation of LC should be established.
Key word : Lyophilized Cryoprecipitate, Hemophilia, Efficacy, Safety
Download:
PDF